• Sign In
  • FAQ
  • Create an Account
Currency
USD currency flagUSD
Toggle Nav
My Cart
Menu
Account
Settings
Currency
USD currency flagUSD

Bcl-2 Family

Shop By
Clear All

Items 1-50 of 62

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. A10665
    Obatoclax mesylate (GX15-070)

    Bcl-2 Inhibitor

    Bcl-2 homology domain-3 (BH3) mimetic,antagonize all antiapoptotic Bcl-2 family proteins (average IC50, 3 umol/L), including Mcl-1 (IC50, 2.9 umol/L) and Bfl-1 (IC50, 5 umol/L).
    Quick View
  2. A12500
    ABT-199 (Venetoclax)

    Bcl-2 inhibitor

    ABT-199 is a so-called BH3-mimetic drug, which is designed to block the function of the protein Bcl 2.
    Quick View
  3. A12823
    Sabutoclax

    Bcl-2 inhibitor

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
    Quick View
  4. A11988
    Gambogic acid

    Bcl-2 inhibitor

    Gambogic acid is a natural product isolated from the Garcinia hanburyi tree. Gambogic Acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 μM, respectively.
    Quick View
  5. A10255
    ABT-737

    Bcl-2 Inhibitor

    ABT-737 is a pan-Bcl-2 inhibitor. IC50 values ranged from 192 nM (the pre-B cell line Hal-01) to <10 μM (Nalm-6, K562 and HL-60).
    Quick View
  6. A13652
    AVN-944

    IMPDH inhibitor

    AVN-944 (also known as VX-944) serves as an effective oral inhibitor, specifically targeting and inhibiting IMPDH (inosine monophosphate dehydrogenase). This enzyme plays a crucial role as a rate-limiting factor in the synthesis of guanine nucleotides from scratch. Additionally, AVN-944 acts against the synthesis of RNA in arenaviruses, effectively preventing arenavirus infections. Demonstrating a wide spectrum of anti-cancer properties, AVN-944 is utilized in research related to multiple myeloma (MM) and acute myeloid leukemia (AML).

    Quick View
  7. A10022
    ABT-263 (Navitoclax)

    Bcl-2 inhibitor

    ABT-263 also called Navitoclax is a potent and orally bioavailable Bcl-2 family inhibitor (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w). it maintains a high affinity for Bcl-xL, Bcl-2, and Bcl-w, (Ki ≤1 nmol/L), but binds more weakly to Mcl-1 and A1.
    Quick View
  8. A13580
    Bcl-2 Inhibitor

    Bcl-2 Inhibitor

    Bcl-2 Inhibitor contains a mixture of two tautomers. A potent, cell-permeable, Bcl-2 inhibitor competes with Bak BH3 peptide for binding to Bcl-2 and Bcl-XL in vitro (IC50 =10 uM and 7 uM, respectively).
    Quick View
  9. A15545
    A-1210477

    MCL-1 inhibitor

    A-1210477 is a potent and selective MCL-1 inhibitor. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines.
    Quick View
  10. A16112
    A-1155463

    BCL-XL inhibitor

    A-1155463 is a highly potent and selective BCL-XL inhibitor, A-1155463 shows picomolar binding affinity to BCL-XL (Ki = <0.01 nM), and >1000-fold weaker binding to BCL-2 (Ki = 80 nM) and related proteins BCL-W (Ki = 19 nM) and MCL-1 (Ki > 440 nM)
    Quick View
  11. A16315
    MIM1

    Mcl-1 inhibitor

    MIM1 is a selective small molecule inhibitor of Mcl-1(IC50= 4.8 μM) that overcomes Mcl-1-dependent leukemia cell survival.
    Quick View
  12. A10955
    TW-37

    Bcl-2 inhibitor

    TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer mediated through a novel pathway involving inactivation of Notch-1 and Jagged-1.
    Quick View
  13. A24979
    BM-1244

    Bcl-xL/Bcl-2 Inhibitor

    BM-1244 is a selective inhibitor of Bcl-xL and Bcl-2, exhibiting Ki values of 134 nM and 450 nM, respectively. This compound induces apoptosis and suppresses tumor growth through the release of cytochrome C and Smac from mitochondria, leading to caspase-3 activation and PARP cleavage. BM-1244 has demonstrated synergistic effects with chemotherapy in vivo, making it a valuable research tool for studying colorectal cancer, acute myeloid leukemia, and gastric cancer.
    Quick View
  14. A24990
    Pelcitoclax

    Bcl-2/Bcl-xl Inhibitor

    Pelcitoclax is a potent inhibitor of Bcl-2 and Bcl-xl, designed to induce apoptosis in cancer cells. Its primary mechanism involves disrupting the anti-apoptotic activity of these proteins, leading to increased cell death in malignant tissues. Pelcitoclax is utilized in research to explore therapeutic strategies against various malignancies and to study apoptotic pathways in cellular models.
    Quick View
  15. A25019
    Lisaftoclax

    Bcl-2/Bcl-xl Inhibitor

    Lisaftoclax is a potent inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-xl. With IC50 values of 2 nM for Bcl-2 and 5.9 nM for Bcl-xl, Lisaftoclax demonstrates significant anti-tumor activity. This compound is primarily utilized in research focused on cancer therapy, particularly in studies exploring mechanisms of apoptosis and the role of Bcl-2 family proteins in tumor survival.
    Quick View
  16. A12743
    BM-1074

    Bcl-2/Bcl-xL inhibitor

    BM-1074 is a potent and efficacious Bcl-2/Bcl-xL inhibitor with Ki of <1 nM.
    Quick View
  17. A13005
    WEHI539

    Bcl-XL inhibitor

    WEHI539 is a selective inhibitor of Bcl-XL with IC50 of 1.1 nM.
    Quick View
  18. A13327
    WEHI-539 hydrochloride

    Bcl-xL inhibitor

    WEHI-539 hydrochloride is a small-molecule inhibitor of BCL-xL with IC50 value of 1.1 nM.
    Quick View
  19. A11448
    HA14-1

    Bcl-2 inhibitor

    HA14-1 interacts with Bcl-2 and inhibits the antiapoptotic effect of Bcl-2.
    Quick View
  20. A13578
    AT101 acetic acid

    pan Bcl-2 inhibitor

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID
    Quick View
  21. A14222
    UMI-77

    Mcl-1 inhibitor

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
    Quick View
  22. A17064
    A-385358

    Bcl-XL inhibitor

    A-385358 is an inhibitor of Bcl-XL that enhances the in vitro cytotoxic activity of numerous chemotherapeutic agents (paclitaxel, etoposide, cisplatin, and doxorubicin) in several tumor cell lines.
    Quick View
  23. A17126
    FX1

    BCL6 inhibitor

    FX1 is an inhibitor of the transcription factor B cell lymphoma 6 (BCL6) with IC50 value of ~35 μM.
    Quick View
  24. A17171
    AZD-4320

    Bcl-2/Bcl-XL inhibitor

    AZD-4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor.
    Quick View
  25. A17206
    Maritoclax (Marinopyrrole A)

    Mcl-1 inhibitor

    Marinopyrrole A, aslo known as Maritoclax, is a selective inhibitor of Mcl-1 with IC50 value of 10.1μM.
    Quick View
  26. A18353
    BT2

    BCKDC kinase (BDK) inhibitor

    BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM.
    Quick View
  27. A18356
    S63845

    myeloid cell leukemia 1 (MCL1) inhibitor

    S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1.
    Quick View
  28. A18359
    (R)-MIK665

    Mcl-1 inhibitor

    (R)-MIK665 is the less active enantiomer of MIK665. MIK665 is a special Mcl-1 inhibitor with an IC50 of 1.81 nM.
    Quick View
  29. A18360
    AMG-176

    MCL-1 inhibitor

    AMG-176 is a potent, selective and orally bioavailable MCL-1 inhibitor, with a Ki of 0.13 nM.
    Quick View
  30. A18361
    S55746

    BCL-2 inhibitor

    S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity.
    Quick View
  31. A18362
    MIK665

    Mcl-1 inhibitor

    MIK665 (S-64315) is a special Mcl-1 inhibitor extracted from patent WO2016207225A1, compound Preparation 13, has an IC50 of 1.81 nM.
    Quick View
  32. A18363
    VU661013

    MCL-1 Inhibitor

    VU661013 is a MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia.
    Quick View
  33. A18364
    ML311

    Mcl-1/Bim interaction inhibitor

    ML311 is a potent and selective inhibitor of the Mcl-1/Bim interaction
    Quick View
  34. A18366
    Mcl1-IN-2

    Mcl-1 inhibitor

    Mcl1-IN-2 is a selective Mcl-1 inhibitor.
    Quick View
  35. A18368
    Mcl1-IN-1

    Mcl-1 inhibitor

    Mcl1-IN-1 is a potent and selective inhibitor of the apoptosis regulating proteins Mcl-1.
    Quick View
  36. A18369
    Mcl-1-PUMA Modulator-8

    Mcl-1-PUMA interface inhibitor

    Mcl1-IN-8 (Comp8) is a Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. Mcl1-IN-8 (Comp8) exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells.
    Quick View
  37. A18372
    Mcl1-IN-9

    Mcl-1 Inhibitor

    Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC50 of 446 nM in reengineered BCR-ABL+ B-ALL cells and a Ki of 0.03 nM.
    Quick View
  38. A18373
    PROTAC Mcl1 degrader-1

    Mcl-1 inhibitor

    PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC), is a potently and selectively Mcl-1 inhibitor with an IC50 of 0.78 μM.
    Quick View
  39. A18374
    NPB

    BAD phosphorylat inhibitor

    NPB is a specific and potent inhibitor of BAD phosphorylation at Ser99, with an IC50 of 0.41 μM.
    Quick View
  40. A18377
    Mcl1-IN-11

    Mcl-1 inhibitor

    Mcl1-IN-11 (Compound G) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.06 and 4.2 μM, respectively.
    Quick View
  41. A18379
    Mcl1-IN-12

    Mcl-1 inhibitor

    Mcl1-IN-12 (Compound F) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.29 and 3.1 μM, respectively. Anti-tumor activity.
    Quick View
  42. A18380
    MCL-1/BCL-2-IN-4

    Mcl-1 and Bcl-2 dual inhibitor

    MCL-1/BCL-2-IN-4 (Compound 7) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor.
    Quick View
  43. A18385
    MCL-1/BCL-2-IN-3

    Mcl-1 and Bcl-2 dual inhibitor

    MCL-1/BCL-2-IN-3 (Compound 2) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor with IC50s of 5.95 and 4.78 μM, respectively.
    Quick View
  44. A18386
    Mcl1-IN-4

    Mcl-1 inhibitor

    Mcl1-IN-4 is an inhibitor of Mcl1 with an IC50 of 0.2 μM.
    Quick View
  45. A18387
    BM 957

    Bcl-2 and Bcl-xL inhibitor

    BM 957 is a potent Bcl-2 and Bcl-xL inhibitor, with Kis of 1.2, <1 nM and IC50s of 5.4, 6.0 nM respectively.
    Quick View
  46. A16190
    A-1331852

    BCL-XL inhibitor

    A-1331852 is a potent and selective BCL-XL inhibitor. BCL-XL is the major antiapoptotic survival protein and may be a novel therapeutic target in CML.
    Quick View
  47. A16192
    CID5721353

    BCL6 inhibitor

    CID5721353 is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor).
    Quick View
  48. A16314
    Apogossypolone (ApoG2)

    Bcl-2 inhibitor

    Apogossypolone is a nonpeptidic small-molecule inhibitor of Bcl-2 with
    Quick View
  49. A16316
    (+)-Apogossypol

    Bcl-2 family inhibitor

    (+)-Apogossypol is a potent inhibitor of Bcl-2 family proteins; competing with the BH3 peptide-binding sites on Bcl-2, Bcl-XL, Mcl-1, Bcl-W, and Bcl-B, but not Bfl-1, with IC50s of 0.5 to 2 μM.
    Quick View
  50. A16323
    (S)-Gossypol acetic acid

    Bcl-2 inhibitor

    (S)-Gossypol acetic acid is a inhibitor of Bcl-2, potently induce cell death in Jurkat cells overexpressing Bcl-2 (IC50, 18.1μM) or Bcl-xL (IC50, 22.9μM).
    Quick View

Items 1-50 of 62

Page
per page
Set Descending Direction
Shop By
Now Shopping by
  1. Actions
    Inhibitor
Clear All